Pulse Biosciences, Inc

PLSE Healthcare Medical Instruments & Supplies

Pulse Biosciences, Inc’s revenue for fiscal 2025 (year ended December 2025) was $350,000.00, down 50.0% from fiscal 2022. In the quarter to June 2026, revenue grew 4,922.2%, EPS fell 28.6% and free cash flow fell 45.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

44.27 1.32 −2.90%
Market cap
$3.3B
P/E
0.0×
Fwd P/E
−19.0×
Dividend yield
—
F-score
n/a
Altman Z
31.41
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
(78.49%) (80.72%) (74.45%) (86.99%)

+8 more TTM periods

ROA
(67.90%) (69.36%) (64.12%) (74.06%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(83.58%) (119.59%) (95.08%) (84.43%)
Average Days of Receivables
37.58 77.23 165.03 6.97
Free Cash Flow per Share
(0.89) (0.82) (0.81) (0.72)
Free Cash Flow
(61.39) (55.50) (54.44) (48.77)
Capital Expenditures
(0.29) (0.30) (0.31) (0.26)
Other line items
Cash ROIC
(30.52%) (41.23%) (33.73%) (25.96%)
Accounts Receivable Turnover
18.66 8.99 4.11 20.68
Accounts Payable Turnover
0.42 0.46 0.50 0.49
Inventory Turnover
8.24 9.96 2.50 0.29
Average Days of Payables
874.52 857.67 915.63 946.01
Days of Inventory on Hand
72.88 63.99 44.84 18.11
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
4,378.57% 6,333.96% 7,379.70% 5,655.98%
Selling, General and Administrative Expense of Revenue
2,629.45% 4,162.94% 5,285.31% 4,363.61%
Share Based Compensation of Revenue
1,474.43% 2,383.83% 3,540.76% 2,961.83%
Operating CF/Net income
0.76 0.74 0.74 0.65
Depreciation/Fixed assets
0.96 1.03 1.02 1.04
Capex/Depreciation
(0.28) (0.29) (0.29) (0.24)
Revenue per Share
0.02 0.01 0.01 0.01
Operating CF per Share
(0.88) (0.81) (0.80) (0.72)
Capex per Share
0.00 0.00 0.00 0.00
Capex to Sales
0.24 0.41 0.52 0.33

Fold the line items

Columns are period end dates